Comments on: Should Amgen’s Sharer Walk The Plank? http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/ News, Comment and Conversation Fri, 10 Feb 2012 20:00:00 +0000 http://wordpress.org/?v=2.6.2 By: VentureBeat » Weekend update: That cold, cold artificial heart, Dendreon-related skulduggery, congressional earmarks, and more http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16876 VentureBeat » Weekend update: That cold, cold artificial heart, Dendreon-related skulduggery, congressional earmarks, and more Mon, 13 Aug 2007 14:46:00 +0000 http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16876 [...] Sharer called on to resign — Also from Pharmalot comes news of an Internet petition demanding the resignation of Amgen’s CEO, who has overseen a sharp decline in the biotech [...] [...] Sharer called on to resign — Also from Pharmalot comes news of an Internet petition demanding the resignation of Amgen’s CEO, who has overseen a sharp decline in the biotech [...]

]]> By: Dr. Mike http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16831 Dr. Mike Mon, 13 Aug 2007 02:11:48 +0000 http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16831 Bye, bye Sharer, and, of course, he has only about "$35 million" worth of reasons and counting (I'm sure with this year's bonus to come after he jettisons enough people in time to "make the numbers" for this year so that he and the other execs get their ridiculous bonuses) to account for why he "doesn't see a crisis". Of course, he doesn't see a crisis for it's too far "beneath" him to be worried about- only the people far below him will be effected. Amgen, what a fall and what a joke these days. Leadership begins and ends at the top as well as the success and failure of organizations and countries (see US of A, Iraq for references). Bye, bye Sharer, and, of course, he has only about “$35 million” worth of reasons and counting (I’m sure with this year’s bonus to come after he jettisons enough people in time to “make the numbers” for this year so that he and the other execs get their ridiculous bonuses) to account for why he “doesn’t see a crisis”. Of course, he doesn’t see a crisis for it’s too far “beneath” him to be worried about- only the people far below him will be effected. Amgen, what a fall and what a joke these days. Leadership begins and ends at the top as well as the success and failure of organizations and countries (see US of A, Iraq for references).

]]> By: Dr. Sal Giorgianni http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16816 Dr. Sal Giorgianni Sun, 12 Aug 2007 18:52:40 +0000 http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16816 Top level leadership is of utmost importance to the health (let alone survival) of any BIO or PhARMA company, particularly these days. These are complex hybrid science based business organizations with very complex products and product lines. They are subject to many economic and sociopolitical factors which often can not be planned let alone averted. It would be irresponsible for me, or anyone outside of the inner circle of a company, to pass judgement on Mr. Sharer, his decisions or his temperment (or to do so for any of the other senior executives of this complex industry who may find themselves in similar difficult spots). Having said that it is the absolute obligation of the Board of these organzations to become engaged - fully engaged - a the earliest signs of such difficulties and help do what they are supposed to do, provide governance and fulfill their fiduciary and moral obligations. They have - or should have - the understanding, insight and capability to review companies and executives when there are some big-old pink flags raise. Without such diligence small flaws can become big ones and the culture of the "yes-(wo)man" can become rampant very quickly. this can set even the strongest corporation on a donward spiral that could take a decade to reverse. So, the burden is squarely on the Amgen Board to do it's job... Top level leadership is of utmost importance to the health (let alone survival) of any BIO or PhARMA company, particularly these days. These are complex hybrid science based business organizations with very complex products and product lines. They are subject to many economic and sociopolitical factors which often can not be planned let alone averted.

It would be irresponsible for me, or anyone outside of the inner circle of a company, to pass judgement on Mr. Sharer, his decisions or his temperment (or to do so for any of the other senior executives of this complex industry who may find themselves in similar difficult spots). Having said that it is the absolute obligation of the Board of these organzations to become engaged - fully engaged - a the earliest signs of such difficulties and help do what they are supposed to do, provide governance and fulfill their fiduciary and moral obligations. They have - or should have - the understanding, insight and capability to review companies and executives when there are some big-old pink flags raise. Without such diligence small flaws can become big ones and the culture of the “yes-(wo)man” can become rampant very quickly. this can set even the strongest corporation on a donward spiral that could take a decade to reverse.

So, the burden is squarely on the Amgen Board to do it’s job…

]]> By: roccaas http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16801 roccaas Sun, 12 Aug 2007 10:30:05 +0000 http://www.pharmalot.com/2007/08/should-amgens-sharer-walk-the-plank/#comment-16801 Ed, thanks for another elegantly written precis of the situation at Amgen. As a loyal Amgenite, I'm sorry to see us spread all over SO MANY papers (and the SEC). I know what Bill Clinton felt like -- I just want to get back to the people's (patient's) business! Ed, thanks for another elegantly written precis of the situation at Amgen. As a loyal Amgenite, I’m sorry to see us spread all over SO MANY papers (and the SEC).

I know what Bill Clinton felt like — I just want to get back to the people’s (patient’s) business!

]]>